Wharton’s Jelly Mesenchymal Stem Cell Administration Improves Quality of Life and Self-Sufficiency in Children with Cerebral Palsy: Results from a Retrospective Study

Table 8

Treatment efficacy in subgroups identified on the basis of improvement in quality of life after the first WJ-MSC administration.

Early response			Average QoL response per one administration in whole later therapy; ( chi^2 with Yates )					Developmental breakthrough; ()						Proportion of patients with developmental breakthrough (improvement in QoL ≥3 between two consecutive assessments)
		Discontinuation after 1^st assessment (n)	<1				≥4	0	1	2	3	4	5
0	10	1	7	1	1	0	0	8	0	0	2	0	0	20%
1	12	3	7	1	1	0	0	8	3	0	1	0	0	8.3%
2	20	4	6	5	5	0	0	13	1	2	2	2	0	20%
3	7	0	4	0	2	1	0	1	1	1	2	2	0	57.1%
4	3	1	0	0	0	2	0	2	0	0	0	1	0	33.3%
5	2	0	0	1	1	0	0	1	0	0	0	1	0	50%

Improvement in quality of life (QoL) after first administration. The highest improvement in QoL between two consecutive assessments. Cells marked in bold represent categorization used in Yates’ chi-square test.